These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 19549278

  • 1. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
    Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K, Kubuki Y, Nagata K, Takenaka K, Akashi K, Okamura T, Niho Y, Mizoguchi H, Omine M, Ozawa K, Harada M, Shimoda K.
    Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
    [Abstract] [Full Text] [Related]

  • 2. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A.
    Cancer; 2006 May 01; 106(9):1985-9. PubMed ID: 16568439
    [Abstract] [Full Text] [Related]

  • 3. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A.
    Eur J Haematol; 2009 Apr 01; 82(4):255-9. PubMed ID: 19215287
    [Abstract] [Full Text] [Related]

  • 4. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K, Van Dyke DL, Tefferi A.
    Eur J Haematol; 2009 May 01; 82(5):329-38. PubMed ID: 19141119
    [Abstract] [Full Text] [Related]

  • 5. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
    Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Simonitsch-Klupp I, Gisslinger H, Zojer N, Ludwig H.
    Cancer; 2006 Dec 15; 107(12):2801-6. PubMed ID: 17103442
    [Abstract] [Full Text] [Related]

  • 6. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
    Tefferi A, Dingli D, Li CY, Dewald GW.
    Cancer; 2005 Oct 15; 104(8):1656-60. PubMed ID: 16104040
    [Abstract] [Full Text] [Related]

  • 7. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
    Reilly JT.
    Semin Oncol; 2005 Aug 15; 32(4):359-64. PubMed ID: 16202681
    [Abstract] [Full Text] [Related]

  • 8. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
    Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S.
    Blood; 2009 Apr 30; 113(18):4171-8. PubMed ID: 19131547
    [Abstract] [Full Text] [Related]

  • 9. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
    Hsiao HH, Ito Y, Sashida G, Ohyashiki JH, Ohyashiki K.
    Leuk Res; 2005 Nov 30; 29(11):1247-52. PubMed ID: 16164981
    [Abstract] [Full Text] [Related]

  • 10. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.
    Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A.
    Blood; 2010 Jan 21; 115(3):496-9. PubMed ID: 19901264
    [Abstract] [Full Text] [Related]

  • 11. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.
    Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW.
    Br J Haematol; 2001 Jun 21; 113(3):763-71. PubMed ID: 11380468
    [Abstract] [Full Text] [Related]

  • 12. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
    Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A.
    Leukemia; 2018 May 21; 32(5):1189-1199. PubMed ID: 29472717
    [Abstract] [Full Text] [Related]

  • 13. Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature.
    Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M.
    Pathol Res Pract; 2012 Jul 15; 208(7):420-3. PubMed ID: 22658480
    [Abstract] [Full Text] [Related]

  • 14. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
    Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A.
    Leukemia; 2011 Jan 15; 25(1):82-8. PubMed ID: 20944670
    [Abstract] [Full Text] [Related]

  • 15. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
    Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.
    Br J Haematol; 2015 Apr 15; 169(1):71-6. PubMed ID: 25521305
    [Abstract] [Full Text] [Related]

  • 16. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A.
    Cytometry B Clin Cytom; 2008 May 15; 74(3):139-49. PubMed ID: 18061951
    [Abstract] [Full Text] [Related]

  • 17. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
    Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP.
    Eur J Haematol; 2009 Jul 15; 83(1):17-21. PubMed ID: 19236446
    [Abstract] [Full Text] [Related]

  • 18. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
    Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M.
    Cancer Genet Cytogenet; 2007 Feb 15; 173(1):57-62. PubMed ID: 17284371
    [Abstract] [Full Text] [Related]

  • 19. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P, Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON), Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC).
    Br J Haematol; 2007 Feb 15; 136(4):615-23. PubMed ID: 17223915
    [Abstract] [Full Text] [Related]

  • 20. Karyotype and molecular cytogenetic studies in polycythemia vera.
    Andrieux JL, Demory JL.
    Curr Hematol Rep; 2005 May 15; 4(3):224-9. PubMed ID: 15865876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.